Christopher Joyce, an insider at Alignment Healthcare, sold 25,125 shares worth $448,230 at an average price of $17.84, reducing his stake by 7.21%. The company recently reported strong Q4 revenue growth of 44.4% year-over-year and an earnings beat, but also faces negative sentiment due to clustered insider selling and a planned secondary offering by a major shareholder. Despite this, several analysts maintain a positive outlook with Buy ratings and raised price targets. The stock trades near its 50-day moving average with high institutional ownership, indicating that future price moves may depend heavily on institutional investors' actions.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
BlackRock reported quarterly earnings per share of $13.91, surpassing analyst estimates of $12.69, and revenue of $7.08 billion, exceeding expectations of $6.73 billion. The company’s assets under management reached a record $15.3 trillion, a 22% inc...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
